Biostem Technologies (BSEM) Q4 2024 earnings summary

Executive summary

• Achieved record Q4 2024 revenue of $102.9 million and full-year revenue of $301.8 million, driven by nationwide launches and strong demand for AmnioWrap2 and Vendaje AC.

• Reported fourth consecutive quarter of profitability, with Q4 GAAP net income of $15.5 million and full-year net income of $31.9 million.

• Gross margin reached 97% in Q4 and 95% for the year, reflecting operational efficiency and successful product launches.

• Strategic focus on expanding clinical validation, payer coverage, and market penetration, with three clinical trials underway and early data expected by mid-2025.

• Uplisting to Nasdaq is pending final SEC resolution on revenue recognition; all other requirements are met.

Financial highlights

• Q4 2024 net revenue: $102.9 million (up 791% year-over-year); full year 2024 net revenue: $301.8 million (up 1,709% year-over-year).

• Q4 gross profit: $99.3 million (97% margin); full year gross profit: $288.1 million (95% margin).

• Q4 adjusted EBITDA: $11.1 million; full year adjusted EBITDA: $39.4 million.

• Q4 net income: $15.5 million ($0.94/share); full year net income: $31.9 million ($1.95/share).

• Operating expenses increased due to workforce expansion, distributor fees, product launch costs, and share-based compensation.

Outlook and guidance

• Expectation of continued financial growth, clinical validation, and expanded payer coverage in 2025.

• No formal revenue guidance provided, but management confident in sustaining momentum due to delayed CMS LCD implementation and ongoing clinical trials.

• Estimated effective tax rate of 24% going forward, as all NOLs have been utilized.

• Uplisting to Nasdaq pending SEC review, with financials subject to final audit and possible adjustments.